Screened 2026-08-26 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Kailera Therapeutics, Inc. holds its Distribution at $18.44.
As held on the ledger · 2026-08-26
Phase
Distribution · caution
Price at the screen
$18.44
Valuation
N/A trailing · -4.29 forward price to earnings
Values screen
Not scored· score 70.0
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.55%
Below 33%
Interest-bearing debt is just 1.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
15.41%
Below 33%
Cash held in interest-bearing accounts and securities is 15.4% of assets, under the one-third limit.
Pass
Receivables
23.54%
Below 49%
Money owed to the company is 23.5% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +122% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical obesity biotech lacks data for any call
Picture a lab racing to treat the global weight problem with new peptides. Kailera sits in that pack but shows zero profit margin, negative forward earnings and no financial ratios at all. With an unknown moat and an ethical screen that returns insufficient data, the setup fails every basic filter we apply before risking capital.
The analyst price targets sit well above the current share price and the implied margin of safety looks large on paper. None of that matters when the company remains pre-revenue and the only available numbers are forecasts. Strong buy ratings from five analysts cannot fill the gap left by missing fundamentals.
Risk sits high because clinical-stage drug developers burn cash for years with binary trial outcomes and no proven commercial edge. Currency or emerging-market exposure is absent here yet the lack of any usable financial history still blocks a clean verdict. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KLRA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-29Accumulation$18.44Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (5 analysts) rates it strong buy, with a mean price target of $43.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.